Cargando…
Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment
Systemic Sclerosis (SSc) is a rheumatic disease characterized by fibrosis, microvascular damage and immune dysregulation. Two major subsets, limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc) can be defined, according to the extent of skin involvement. Incr...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093796/ https://www.ncbi.nlm.nih.gov/pubmed/33959016 http://dx.doi.org/10.3389/fphar.2021.650605 |
_version_ | 1783687890984763392 |
---|---|
author | Sundblad, Victoria Gomez, Ramiro A. Stupirski, Juan C. Hockl, Pablo F. Pino, Maria S. Laborde, Hugo Rabinovich, Gabriel A. |
author_facet | Sundblad, Victoria Gomez, Ramiro A. Stupirski, Juan C. Hockl, Pablo F. Pino, Maria S. Laborde, Hugo Rabinovich, Gabriel A. |
author_sort | Sundblad, Victoria |
collection | PubMed |
description | Systemic Sclerosis (SSc) is a rheumatic disease characterized by fibrosis, microvascular damage and immune dysregulation. Two major subsets, limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc) can be defined, according to the extent of skin involvement. Increasing evidence indicates a role for galectins in immune and vascular programs, extracellular matrix remodeling and fibrosis, suggesting their possible involvement in SSc. Here, we determined serum levels of galectin (Gal)-1 and Gal-3 in 83 SSc patients (dcSSc n = 17; lcSSc n = 64; ssSSc n = 2), and evaluated their association with clinical manifestations of the disease. Patients with dcSSc showed lower Gal-3 levels, compared to lcSSc (p = 0.003), whereas no considerable difference in Gal-1 levels was detected between groups. Remarkably, higher concentrations of Gal-1 were associated with the presence of telangiectasias (p = 0.015), and higher concentrations Gal-3 were associated with telangiectasias (p = 0.021), diarrhea (p = 0.039) and constipation (p = 0.038). Moreover, lower Gal-3 levels were associated with the presence of tendinous retractions (p = 0.005). Patients receiving calcium blockers (p = 0.048), methotrexate (p = 0.046) or any immunosuppressive treatment (p = 0.044) presented lower concentrations of Gal-3 compared to those not receiving such treatments. The presence of telangiectasia and the type of SSc maintained their statistical association with Gal-3 (β 0.25; p = 0.022 and β 0.26; p = 0.017, respectively) in multiple linear regression models. In conclusion, serum levels of Gal-3 are associated with clinical manifestations of SSc. Among them, the presence of telangiectasias could be explained by the central role of this lectin in the vascularization programs. |
format | Online Article Text |
id | pubmed-8093796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80937962021-05-05 Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment Sundblad, Victoria Gomez, Ramiro A. Stupirski, Juan C. Hockl, Pablo F. Pino, Maria S. Laborde, Hugo Rabinovich, Gabriel A. Front Pharmacol Pharmacology Systemic Sclerosis (SSc) is a rheumatic disease characterized by fibrosis, microvascular damage and immune dysregulation. Two major subsets, limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc) can be defined, according to the extent of skin involvement. Increasing evidence indicates a role for galectins in immune and vascular programs, extracellular matrix remodeling and fibrosis, suggesting their possible involvement in SSc. Here, we determined serum levels of galectin (Gal)-1 and Gal-3 in 83 SSc patients (dcSSc n = 17; lcSSc n = 64; ssSSc n = 2), and evaluated their association with clinical manifestations of the disease. Patients with dcSSc showed lower Gal-3 levels, compared to lcSSc (p = 0.003), whereas no considerable difference in Gal-1 levels was detected between groups. Remarkably, higher concentrations of Gal-1 were associated with the presence of telangiectasias (p = 0.015), and higher concentrations Gal-3 were associated with telangiectasias (p = 0.021), diarrhea (p = 0.039) and constipation (p = 0.038). Moreover, lower Gal-3 levels were associated with the presence of tendinous retractions (p = 0.005). Patients receiving calcium blockers (p = 0.048), methotrexate (p = 0.046) or any immunosuppressive treatment (p = 0.044) presented lower concentrations of Gal-3 compared to those not receiving such treatments. The presence of telangiectasia and the type of SSc maintained their statistical association with Gal-3 (β 0.25; p = 0.022 and β 0.26; p = 0.017, respectively) in multiple linear regression models. In conclusion, serum levels of Gal-3 are associated with clinical manifestations of SSc. Among them, the presence of telangiectasias could be explained by the central role of this lectin in the vascularization programs. Frontiers Media S.A. 2021-04-20 /pmc/articles/PMC8093796/ /pubmed/33959016 http://dx.doi.org/10.3389/fphar.2021.650605 Text en Copyright © 2021 Sundblad, Gomez, Stupirski, Hockl, Pino, Laborde and Rabinovich. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Sundblad, Victoria Gomez, Ramiro A. Stupirski, Juan C. Hockl, Pablo F. Pino, Maria S. Laborde, Hugo Rabinovich, Gabriel A. Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment |
title | Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment |
title_full | Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment |
title_fullStr | Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment |
title_full_unstemmed | Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment |
title_short | Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment |
title_sort | circulating galectin-1 and galectin-3 in sera from patients with systemic sclerosis: associations with clinical features and treatment |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093796/ https://www.ncbi.nlm.nih.gov/pubmed/33959016 http://dx.doi.org/10.3389/fphar.2021.650605 |
work_keys_str_mv | AT sundbladvictoria circulatinggalectin1andgalectin3inserafrompatientswithsystemicsclerosisassociationswithclinicalfeaturesandtreatment AT gomezramiroa circulatinggalectin1andgalectin3inserafrompatientswithsystemicsclerosisassociationswithclinicalfeaturesandtreatment AT stupirskijuanc circulatinggalectin1andgalectin3inserafrompatientswithsystemicsclerosisassociationswithclinicalfeaturesandtreatment AT hocklpablof circulatinggalectin1andgalectin3inserafrompatientswithsystemicsclerosisassociationswithclinicalfeaturesandtreatment AT pinomarias circulatinggalectin1andgalectin3inserafrompatientswithsystemicsclerosisassociationswithclinicalfeaturesandtreatment AT labordehugo circulatinggalectin1andgalectin3inserafrompatientswithsystemicsclerosisassociationswithclinicalfeaturesandtreatment AT rabinovichgabriela circulatinggalectin1andgalectin3inserafrompatientswithsystemicsclerosisassociationswithclinicalfeaturesandtreatment |